T-cell Lymphoma Clinical Trials in Beijing, Beijing Municipality
7 recruitingBeijing, Beijing Municipality, China
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
T-cell LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPTCL
Peking University People's Hospital30 enrolled1 locationNCT06874946
Recruiting
Phase 1Phase 2
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
T-cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)
Beijing GoBroad Hospital36 enrolled4 locationsNCT06925464
Recruiting
Phase 2
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
Natural Killer/T-cell Lymphoma
Sun Yat-sen University47 enrolled2 locationsNCT06733051
Recruiting
Phase 1Phase 2
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
T-cell LymphomaT-cell Prolymphocytic LeukemiaT-cell Acute Lymphoblastic Leukemia+3 more
Essen Biotech60 enrolled1 locationNCT06420076
Recruiting
Phase 1Phase 2
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Relapsed Peripheral T-Cell LymphomasRefractory Peripheral T-Cell Lymphomas
Navy General Hospital, Beijing52 enrolled1 locationNCT06176027
Recruiting
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Cutaneous T Cell LymphomaCutaneous T-Cell Lymphoma/Mycosis Fungoides
Peking University First Hospital100 enrolled3 locationsNCT06436677
Recruiting
Phase 1Phase 2
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
T-lymphoblastic LymphomaNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Beijing Tongren Hospital43 enrolled1 locationNCT06376721